Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000937314) titled 'A study to evaluate the activity and safety of pembrolizumab in combination with sacituzumab tirumotecan in mismatch repair proficient advanced or recurrent endometrial cancer' on July 29.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety/efficacy
Primary Sponsor: The University of Sydney
Condition:
Endometrial cancer
Endometrial cancer
Cancer - Womb (Uterine or endometrial cancer)
Intervention:
Pembrolizumab 400 mg intravenous infusion every 6 weeks (maximum 2 years) and sacituzu...